Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DN2W9I
|
|||
| Drug Name |
ATYR1923
|
|||
| Synonyms |
Efzofitimod
Click to Show/Hide
|
|||
| Drug Type |
Fusion protein
|
|||
| Indication | Pulmonary sarcoidosis [ICD-11: 4B20.0; ICD-10: D86.0] | Phase 3 | [1] | |
| Company |
ATyr Pharma
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Neuropilin-2 (NRP2) | Target Info | . | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT05415137) A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Intravenous Efzofitimod in Patients With Pulmonary Sarcoidosis. U.S.National Institutes of Health. | |||
| REF 2 | Efzofitimod for the Treatment of Pulmonary Sarcoidosis. Chest. 2023 Apr;163(4):881-890. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.